IP Library Granted Patent US 9,572,814
Granted Patent B2
US 9,572,814 · App. 13/653,213 · Granted Feb 21, 2017

Methods of improving the pharmacokinetics of doxepin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,572,814
App. No.
13/653,213
Granted
Feb 21, 2017
Kind
B2
Abstract

Methods of improving the pharmacokinetics of doxepin in a patient.

Claims (16)

1. A method of treating insomnia, the method comprising

administering between about 0.5 mg and about 7 mg doxepin to a patient in need thereof, wherein the doxepin is administered before bedtime and at least three hours after consuming a meal, thereby providing a faster onset of action and reducing next day residual effects.

2. The method of claim 1 , wherein the doxepin is administered in an amount of about 3 milligrams.

3. The method of claim 1 wherein the doxepin is administered in an amount of about 6 milligrams.

4. The method of claim 1 wherein the doxepin is administered as a tablet, capsule or liquid.

5. The method of claim 1 , wherein the doxepin is administered as a unit dosage form.

6. The method of claim 1 , wherein the doxepin is administered as an oral dosage form.

7. The method of claim 1 , wherein the doxepin is administered within about one hour of bedtime.

8. A method for treating sleep maintenance insomnia, the method comprising:

administering between about 1 mg and about 6 mg doxepin to a patient in need thereof, wherein the doxepin is administered within about one hour before bedtime and at least three hours after consuming a meal, thereby providing a faster onset of action and reducing next day residual effects.

9. The method of claim 8 , wherein the doxepin is administered in an amount of about 3 mg.

10. The method of claim 8 , wherein the doxepin is administered in an amount of about 6 mg.

11. The method of claim 8 , wherein the doxepin is administered as a tablet, capsule or liquid.

12. The method of claim 8 , wherein the method shortens the median time to reach maximum plasma concentration (T max ) of doxepin in the patient compared to administering the doxepin with a high fat meal.

13. The method of claim 8 , wherein the method decreases the maximum plasma concentration (C max ) of doxepin in the patient compared to administering the doxepin with a high fat meal.

14. The method of claim 8 , wherein the method decreases the area under the curve (AUC) of doxepin in the patient compared to administering the doxepin with a high fat meal.

Assignments (8)
SECURITY INTEREST Recorded Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2019
From: PERNIX SLEEP, INC.
To: CURRAX PHARMACEUTICALS LLC
Reel/Frame 049329/0730 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2015
From: PERNIX THERAPEUTICS HOLDINGS, INC.
To: PERNIX SLEEP, INC.
Reel/Frame 036387/0667 →
RELEASE OF SECURITY INTEREST IN PATENT RIGHTS REEL/FRAME 030441/0229 Recorded Feb 24, 2014
From: MIDCAP FUNDING IV, LLC (SUCCESSOR IN INTEREST TO MIDCAP FINANCIAL, LLC)
To: PERNIX SLEEP, INC.
Reel/Frame 032330/0023 →
MERGER Recorded Feb 3, 2014
From: SOMAXON PHARMACEUTICALS, INC.
To: PERNIX THERAPEUTICS HOLDINGS, INC.
Reel/Frame 032118/0272 →
PATENT TRANSFER AND ASSIGNMENT Recorded Sep 13, 2013
From: MIDCAP FINANCIAL, LLC
To: MIDCAP FUNDING IV, LLC
Reel/Frame 031266/0572 →
PATENT TRANSFER AND ASSIGNMENT Recorded Sep 13, 2013
From: MIDCAP FUNDING V, LLC
To: MIDCAP FINANCIAL, LLC
Reel/Frame 031266/0437 →
SECURITY AGREEMENT Recorded May 17, 2013
From: PERNIX SLEEP, INC.
To: MIDCAP FINANCIAL, LLC
Reel/Frame 030441/0229 →